Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 21, 2026, 6:15 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 77 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: ethinyl estradiol-levonorgestrel Clear all
Completed Phase 3 Interventional Accepts healthy volunteers

A Study to Evaluate Suppression of the Pituitary-Ovarian Axis With Three Different Oral Contraceptive Regimens

NCT00117273
View directory record Official record
Conditions
Healthy
Interventions
Seasonale [levonorgestrel (LNG)/ethinyl estradiol (EE)], Seasonique (LNG/EE and EE), Portia (LNG/EE)
Drug
Lead sponsor
Duramed Research
Industry
Eligibility
18 Years to 35 Years · Female only
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
1
States / cities
Temple, Texas
Source: ClinicalTrials.gov public record
Updated May 8, 2014 · Synced Sep 21, 2026, 6:15 PM EDT
Terminated Phase 4 Interventional Results available

Protease Inhibitors and Combined Oral Contraceptive Pharmacokinetics and Pharmacodynamics

NCT02531321
View directory record Official record
Conditions
Contraception, HIV
Interventions
Levonorgestrel and Ethinyl Estradiol
Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 30, 2019 · Synced Sep 21, 2026, 6:15 PM EDT
Terminated Phase 2 Interventional Results available

A Safety & Efficacy Study of BGS649 in Women With Refractory Endometriosis

NCT01116440
View directory record Official record
Conditions
Pelvic Pain Associated With Refractory Endometriosis
Interventions
BGS649, Placebo
Drug
Lead sponsor
Mereo BioPharma
Industry
Eligibility
18 Years to 49 Years · Female only
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
42
States / cities
Mobile, Alabama • Phoenix, Arizona • Jonesboro, Arkansas + 36 more
Source: ClinicalTrials.gov public record
Updated Nov 22, 2020 · Synced Sep 21, 2026, 6:15 PM EDT
Completed No phase listed Observational Results available

Oral Contraceptive Hormone-free Interval Pituitary/ Ovarian Activity

NCT01953211
View directory record Official record
Conditions
Hypothalamic-pituitary-ovarian Axis, Gonadotropins, Ethinyl Estradiol, Contraceptive Efficacy
Interventions
combined oral contraceptives
Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years to 35 Years · Female only
Enrollment
64 participants
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 25, 2019 · Synced Sep 21, 2026, 6:15 PM EDT
Completed Not applicable Interventional Results available

Managing Temporomandibular Disorder (TMD) Symptoms

NCT00237042
View directory record Official record
Conditions
Temporomandibular Joint Disorders
Interventions
Self Management, Targeted Self Management, 20 mcg ethinyl estradiol and 100 mcg levonorgestrel
Behavioral · Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 10, 2011 · Synced Sep 21, 2026, 6:15 PM EDT
Not listed Phase 1 Interventional

A Study to Assess the Effect of Venetoclax on Ethinyl Estradiol and Levonorgestrel in Female Participants With Different Hematological Malignancies

NCT03557619
View directory record Official record
Conditions
Hematologic Malignancies
Interventions
Venetoclax, ethinyl estradiol/levonorgestrel
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older · Female only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
3
States / cities
Detroit, Michigan • Lebanon, New Hampshire • Canton, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 28, 2024 · Synced Sep 21, 2026, 6:15 PM EDT
Completed Phase 1 Interventional

A Study of ABBV-295 Subcutaneous Injections to Assess Pharmacokinetics and Adverse Events in Healthy Adult Women Participants With Overweight or Obesity Taking Oral Contraceptives

NCT07414784
View directory record Official record
Conditions
Healthy Volunteer
Interventions
ABBV-295, Levonorgestrel/Ethinyl Estradiol
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
2
States / cities
Anaheim, California • Grayslake, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 30, 2026 · Synced Sep 21, 2026, 6:15 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Efficacy and Safety of DR-103 for the Prevention of Pregnancy

NCT00996580
View directory record Official record
Conditions
Pregnancy Prevention
Interventions
DR-103
Drug
Lead sponsor
Teva Women's Health
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
3,597 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
94
States / cities
Montgomery, Alabama • Phoenix, Arizona • Tucson, Arizona + 83 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2013 · Synced Sep 21, 2026, 6:15 PM EDT
Completed Phase 3 Interventional

Study Evaluating Combination of Levonorgestrel (LNG) and Ethinyl Estradiol (EE) in Premenstrual Dysphoric Disorder

NCT00128934
View directory record Official record
Conditions
Menstruation Disturbances, Premenstrual Syndrome
Interventions
levonorgestrel/ethinyl estradiol
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years to 49 Years · Female only
Enrollment
744 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
69
States / cities
Scottsdale, Arizona • Tucson, Arizona • Jonesboro, Arkansas + 61 more
Source: ClinicalTrials.gov public record
Updated Dec 26, 2007 · Synced Sep 21, 2026, 6:15 PM EDT
Completed Phase 4 Interventional Results available

Medical Therapy Versus Radiofrequency Endometrial Ablation in the Initial Treatment of Menorrhagia

NCT01165307
View directory record Official record
Conditions
Menorrhagia
Interventions
Estradiol 30mcg / Levonorgestrel 150mcg monophasic oral contraceptive pills, Naproxen sodium pills, NovaSure® Radiofrequency Endometrial Ablation
Drug · Device
Lead sponsor
Abimbola Famuyide
Other
Eligibility
30 Years to 55 Years · Female only
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 19, 2017 · Synced Sep 21, 2026, 6:15 PM EDT
Completed Early Phase 1 Interventional

Inpatient Adolescent Contraception

NCT04423068
View directory record Official record
Conditions
Pregnancy Related, Contraception, Contraceptive Usage, Contraception Behavior, Pregnancy
Interventions
SexHealth II, Contraceptive
Behavioral · Drug
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
14 Years to 21 Years · Female only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 4, 2023 · Synced Sep 21, 2026, 6:15 PM EDT
Not yet recruiting Phase 1 Interventional Accepts healthy volunteers

A Study of Eloralintide (LY3841136) in Female Participants With Obesity or Overweight

NCT07808060
View directory record Official record
Conditions
Obesity, Overweight
Interventions
Eloralintide, Combined oral contraceptive
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 60 Years · Female only
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
2
States / cities
Daytona Beach, Florida • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 7, 2026 · Synced Sep 21, 2026, 6:15 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Efficacy of Seasonique for the Treatment of Cyclic Pelvic Pain

NCT00196313
View directory record Official record
Conditions
Dysmenorrhea
Interventions
levonorgestrel/EE 0.15/0.03 and EE 0.01 mg tablets, Placebo tablet
Drug
Lead sponsor
Duramed Research
Industry
Eligibility
Up to 17 Years · Female only
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
13
States / cities
Denver, Colorado • Decatur, Georgia • Louisville, Kentucky + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2016 · Synced Sep 21, 2026, 6:15 PM EDT
Completed Phase 3 Interventional

A Study to Evaluate the Efficacy of Seasonique for the Treatment of Cyclic Pelvic Pain

NCT00196365
View directory record Official record
Conditions
Dysmenorrhea
Interventions
levonorgestrel/EE 0.15/0.03 and EE 0.01 mg tablets, levonorgestrel/EE 0.15/0.03 mg tablets and placebo
Drug
Lead sponsor
Duramed Research
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
18
States / cities
Huntsville, Alabama • Phoenix, Arizona • San Diego, California + 14 more
Source: ClinicalTrials.gov public record
Updated May 11, 2014 · Synced Sep 21, 2026, 6:15 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Research Study Looking Into How NNC0662-0419 Works With Birth Control Pills and Emptying of the Stomach in Women Not Able to Become Pregnant With Excess Body Weight

NCT07525791
View directory record Official record
Conditions
Overweight, Obesity
Interventions
NNC0662-0419, Oral contraceptive, Acetaminophen
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 64 Years · Female only
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Sep 21, 2026, 6:15 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Obesity, Oral Contraception, and Ovarian Suppression

NCT00827632
View directory record Official record
Conditions
Ovarian Suppression
Interventions
Low dose formulation, High dose formulation
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 35 Years · Female only
Enrollment
226 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 29, 2019 · Synced Sep 21, 2026, 6:15 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Pharmacokinetic Study of AG200-15 Transdermal Patch to Three Anatomical Sites in Healthy Females

NCT01422135
View directory record Official record
Conditions
Healthy
Interventions
AG200-15
Drug
Lead sponsor
Agile Therapeutics
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
2
States / cities
Lincoln, Nebraska • Neptune City, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 30, 2018 · Synced Sep 21, 2026, 6:15 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Drug Interaction Between Povorcitinib and the Oral Contraceptive Levonorgestrel/Ethinyl Estradiol in Healthy Adult Females

NCT06380205
View directory record Official record
Conditions
Healthy Participants
Interventions
Povorcitinib, Levonorgestrel/Ethinyl estradiol
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years to 60 Years · Female only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 2, 2024 · Synced Sep 21, 2026, 6:15 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Multicenter Study to Evaluate the Effects of a 91-Day Extended Cycle Oral Contraceptive on Hemostatic Parameters in Healthy Women

NCT01252186
View directory record Official record
Conditions
Hemostasis, Oral Contraceptive
Interventions
91-day Levonorgestrel Oral Contraceptive, 28-day Levonorgestrel Oral Contraceptive, 28-day Desogestrel Oral Contraceptive
Drug
Lead sponsor
Teva Women's Health
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
265 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
21
States / cities
San Diego, California • Washington D.C., District of Columbia • Miami, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2015 · Synced Sep 21, 2026, 6:15 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Impact of Combined Hormonal Contraceptives on UPA

NCT02577601
View directory record Official record
Conditions
Contraception
Interventions
Ulipristal Acetate, Levonorgestrel (LNG)/Ethinyl estradiol birth control pill
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 35 Years · Female only
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Nov 7, 2019 · Synced Sep 21, 2026, 6:15 PM EDT
Completed Phase 2 Interventional Results available

A Multicenter Study to Evaluate the Efficacy of a 91-Day Extended Cycle Oral Contraceptive for Menstrually-Related Migraine Headaches

NCT00781456
View directory record Official record
Conditions
Migraine
Interventions
91-day Levonorgestrel Oral Contraceptive, Placebo
Drug
Lead sponsor
Duramed Research
Industry
Eligibility
18 Years to 34 Years · Female only
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
22
States / cities
La Mesa, California • San Diego, California • San Francisco, California + 18 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2017 · Synced Sep 21, 2026, 6:15 PM EDT
Recruiting Phase 2 Interventional

Role of Estrogen on Skeletal Outcomes in FHA

NCT07010146
View directory record Official record
Conditions
Bone Strength, Bone Density, FHA (Functional Hypothalamic Amenorrhea)
Interventions
transdermal 17β-E2 with cyclic progestin, oral 17β-E2 with cyclic progestin, transdermal EE+LNG
Drug
Lead sponsor
University of Virginia
Other
Eligibility
14 Years to 30 Years · Female only
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
2
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Sep 21, 2026, 6:15 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug-drug Interaction Study of CTP-543 and Oral Contraceptives in Healthy Female Subjects

NCT04309643
View directory record Official record
Conditions
Healthy Volunteers
Interventions
CTP-543, Combined oral contraceptive containing Ethinyl estradiol (EE) and Levonorgestrel (LNG)
Drug
Lead sponsor
Concert Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 15, 2020 · Synced Sep 21, 2026, 6:15 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Pharmacokinetics of Ethinyl Estradiol and Levonorgestrel When Given Alone and in Combination With Baxdrostat in Healthy Females of Non-childbearing Potential

NCT06657105
View directory record Official record
Conditions
Healthy Participants
Interventions
EE/LNG, Baxdrostat
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
35 Years to 75 Years · Female only
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Brooklyn, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 6, 2025 · Synced Sep 21, 2026, 6:15 PM EDT